Intranasal administration

US11052204B2 · kind B2 · utility

Assignee

• OptiNose AS · NO

Inventors

• Per Gisle Djupesland · Oslo, NO
• Ramy A. Mahmoud · Yardley, US
• Ole A Andreassen · Oslo, NO
• Lars T. Westlye · Oslo, NO
• Daniel S. Quintana · Oslo, NO
• Knut T. Smerud · Oslo, NO
• Colin David Sheldrake · Devizes, GB

Key dates

• Filing date: Nov 19, 2015
• Grant date: Jul 6, 2021
• Expiry date: Jan 11, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61M2210/0618
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A delivery device for and method of modulating a condition relating to sodal cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.